We observed that SOX2 and OCT4 expression was significantly increased in tbLCM-treated breast cancer cells as compared to tnLCM or BM treated cells, while expression of SOX9 and NANOG was not different between treatment conditions. The gene discussed is SOX2; the disease is breast cancer.